Adam Kittai, MD, is a Hematologist at the James Cancer Hospital Solove Research Institute, Columbus, OH, and Assistant Professor in the Division of Hematology, Ohio State University, Columbus, OH. Dr Kittai obtained his medical degree at the Sackler School of Medicine, New York, NY, in 2012, before going on to complete his residency in internal medicine at the George Washington University Medical Centre, Washington, DC, in 2016. He then completed his fellowship in hematology/oncology at the Oregon Health & Science University Hospital, Portland, OR, in 2019.
Speaking on chronic lymphocytic leukemia and targeted therapies
Dr Kittai’s chief research interests lie in chronic lymphocytic leukemia (CLL) and its novel therapies. He has extensively been involved in ongoing clinical trials assessing the efficacy of agents such as obinutuzumab, ibrutinib, and venetoclax in CLL patients. He has also been involved in studies investigating the impact of novel genetic variants which affect treatment response in CLL patients.